Disease · MONDO_0004979
Comparisons in its trials458
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 458
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| MF/F MDI BID vs MF MDI BID: deaths from any cause | 5 of 5,868 | 4 of 5,861 | 11,729 | NCT01471340 | Trial comparisons |
| MF/F MDI BID vs MF MDI BID: serious adverse events | 136 of 5,868 | 137 of 5,861 | 11,729 | NCT01471340 | Trial comparisons |
| Symbicort vs Budesonide: Number of Participants Experiencing an Event in the Composite Endpoint (Asthma-related Death, Asthma-related Intubation or Asthma-related Hospitalization) | 43 of 5,846 | 40 of 5,847 | 11,693 | NCT01444430 | Trial comparisons |
| Symbicort vs Budesonide: Number of Participants Experiencing Discontinuation of Investigational Product Due to a Protocol Defined Asthma Exacerbation | 53 of 5,846 | 71 of 5,847 | 11,693 | NCT01444430 | Trial comparisons |
| Symbicort vs Budesonide: Number of Participants Experiencing an Event Included in the Definition of Asthma Exacerbation | 539 of 5,846 | 633 of 5,847 | 11,693 | NCT01444430 | Trial comparisons |
| Symbicort vs Budesonide: serious adverse events | 125 of 5,846 | 123 of 5,847 | 11,693 | NCT01444430 | Trial comparisons |
| Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): Number of Participants Experiencing at Least One Asthma Exacerbation | 480 of 5,834 | 597 of 5,845 | 11,679 | NCT01475721 | Trial comparisons |
| Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): Number of Participant Withdrawals From Study Treatment Due to Asthma Exacerbation | 66 of 5,834 | 84 of 5,845 | 11,679 | NCT01475721 | Trial comparisons |
Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death) | 34 of 5,834 | 33 of 5,845 | 11,679 | NCT01475721 | Trial comparisons |
| Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP): serious adverse events | 134 of 5,834 | 125 of 5,845 | 11,679 | NCT01475721 | Trial comparisons |
| Symbicort® SMART®) 1*2 vs Symbicort® SMART®) 2*2: serious adverse events | 77 of 4,008 | 88 of 4,045 | 8,053 | NCT00463866 | Trial comparisons |
| FSC DPI vs FP DPI: Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment Period | 265 of 3,107 | 309 of 3,101 | 6,208 | NCT01462344 | Trial comparisons |
FSC DPI vs FP DPI: Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death) | 27 of 3,107 | 21 of 3,101 | 6,208 | NCT01462344 | Trial comparisons |
| FSC DPI vs FP DPI: Number of Participants Experiencing Asthma-related Endotracheal Intubations Over the 6-month Study Treatment Period | 0 of 3,107 | 0 of 3,101 | 6,208 | NCT01462344 | Trial comparisons |
| FSC DPI vs FP DPI: Number of Participants Experiencing Asthma-related Deaths Over the 6-month Study Treatment Period. | 0 of 3,107 | 0 of 3,101 | 6,208 | NCT01462344 | Trial comparisons |
| FSC DPI vs FP DPI: Number of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period | 27 of 3,107 | 21 of 3,101 | 6,208 | NCT01462344 | Trial comparisons |
| FSC DPI vs FP DPI: serious adverse events | 56 of 3,107 | 54 of 3,101 | 6,208 | NCT01462344 | Trial comparisons |
| FF/VI vs Usual Care: Number of Participants With Fatal SAEs of Pneumonia | 1 of 2,114 | 3 of 2,119 | 4,233 | NCT01706198 | Trial comparisons |
| FF/VI vs Usual Care: Number of Participants With SAEs | 284 of 2,114 | 284 of 2,119 | 4,233 | NCT01706198 | Trial comparisons |
| FF/VI vs Usual Care: Time to First Severe Asthma Exacerbation. | 634 of 2,114 | 654 of 2,119 | 4,233 | NCT01706198 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004979/comparisons